3-iodo-7-methyl-1H-pyrrolo[3,2-b]pyridine | 1190312-40-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 3-iodo-7-methyl-1H-pyrrolo[3,2-b]pyridine
• CAS: 1190312-40-3
• 化学式: C₈H₇IN₂
• 分子量: 258.061
• InChiKey: IDSWTOXKAOXKTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-iodo-7-methyl-1H-pyrrolo[3,2-b]pyridine 在 sodium hydride 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 、 mineral oil 为溶剂， 反应 20.42h， 生成 methyl 1-(5-fluoro-2-methoxybenzyl)-7-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxylate
  参考文献：
  名称：

  Lead Optimization of 1,4-Azaindoles as Antimycobacterial Agents

  摘要：

  In a previous report, we described the discovery of 1,4-azaindoles, a chemical series with excellent in vitro and in vivo antimycobacterial potency through noncovalent inhibition of decaprenylphosphoryl-beta-D-ribose-2'-epimerase (DprE1). Nevertheless, high mouse metabolic turnover and phosphodiesterase 6 (PDE6) off-target activity limited its advancement. Herein, we report lead optimization of this series, culminating in potent, metabolically stable compounds that have a robust pharmacokinetic profile without any PDE6 liability. Furthermore, we demonstrate efficacy for 1,4-azaindoles in a rat chronic TB infection model. We believe that compounds from the 1,4-azaindole series are suitable for in vivo combination and safety studies.

  DOI：

  10.1021/jm500571f
• 作为产物：
  描述：

  7-甲基-5-氮杂吲哚 在 N-碘代丁二酰亚胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以94%的产率得到3-iodo-7-methyl-1H-pyrrolo[3,2-b]pyridine
  参考文献：
  名称：

  [EN] SPIROPIPERIDINE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS
  [FR] SPIROPIPÉRIDINE BENZYLAMINESUTILES COMME INHIBITRICES DE LA BÊTA-TRYPTASE

  摘要：

  本发明公开并声明了一系列式(I)的取代螺环哌啶苄胺化合物，其中R如本文所述。更具体地说，本发明的化合物是β-色胺酶的抑制剂，因此可用作治疗关节炎，包括关节炎、类风湿关节炎和其他关节炎症状，如类风湿脊柱炎、痛风性关节炎、创伤性关节炎、风疹性关节炎、银屑病性关节炎、骨关节炎或其他慢性炎症性关节疾病，或关节软骨破坏疾病、眼结膜炎、春季结膜炎、炎性肠病、哮喘、过敏性鼻炎、间质性肺病、纤维化、硬皮病、肺纤维化、肝硬化、心肌纤维化、神经纤维瘤、肥厚性瘢痕、各种皮肤病症，例如特应性皮炎和银屑病、心肌梗死、中风、心绞痛或动脉粥样硬化斑块破裂的其他后果，以及牙周病、糖尿病视网膜病变、黄斑变性、急性黄斑变性、湿性黄斑变性、肿瘤生长、过敏反应、多发性硬化、消化性溃疡或合胞病毒感染的药物。

  公开号：

  WO2011079103A1

文献信息

• [EN] [4[4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF<br/>[FR] [4[4-(5-AMINOMÉTHYL-2-FLUORO-PHÉNYL)-PIPÉRIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-MÉTHANONES ET LEUR SYNTHÈSE
  申请人：SANOFI SA

  公开号：WO2011078984A1

  公开（公告）日：2011-06-30

  The present invention relates herein to compounds and compositions for the treatment and amelioration of inflammatory disease. Specifically the present invention relates to compounds that having a tryptase inhibition activity and the intermediates thereof, pharmaceutical compositions comprising such compounds, and a method of treating subjects suffering from a condition disease or disorder that can be ameliorated by the administration of an inhibitor of tryptase including but not limited to for example asthma and other inflammatory diseases including age-related macular degeneration.

  本发明涉及用于治疗和改善炎症性疾病的化合物和组合物。特别是，本发明涉及具有胰蛋白酶抑制活性的化合物及其中间体，包括这些化合物的药物组合物，以及治疗可通过施用胰蛋白酶抑制剂来改善的状况、疾病或失调的方法，例如但不限于哮喘和其他炎症性疾病，包括年龄相关的黄斑变性。
• 4-Azaindole Derivatives
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20150094328A1

  公开（公告）日：2015-04-02

  4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.

  4-氮杂吲哚衍生物是肌胆碱受体（mAChR）M1的调节剂，可能对预防或疾病修饰或症状性治疗与神经系统疾病如阿尔茨海默病（AD）或带有Lewy小体的痴呆症相关的认知缺陷有效，并且包括4-氮杂吲哚衍生物作为活性成分的药物组合物。
• [EN] SPIROPIPERIDINE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS<br/>[FR] SPIROPIPÉRIDINE BENZYLAMINESUTILES COMME INHIBITRICES DE LA BÊTA-TRYPTASE
  申请人：SANOFI SA

  公开号：WO2011079103A1

  公开（公告）日：2011-06-30

  The present invention discloses and claims a series of substituted spiropiperidine benzylamines of formula (I) wherein R is as described herein. More specifically, the compounds of this invention are inhibitors of β-tryptase and are, therefore, useful as pharmaceutical agents for treating joint inflammation, including arthritis, rheumatoid arthritisand other arthritic condition such as rheumatoid spondylitis, gouty arthπtis, traumatic arthritis, rubella arthritis, psoriatic arthritis, osteoarthritis or other chronic inflammatory joint disease, or diseases of joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, interstitial lung diseases, fibrosis, sceleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, neurofibromas, hypertrophic scars, various dermatological conditions, for example, atopic dermatitis and psoriasis, myocardial infarction, stroke, angina or other consequences of atherosclerotic plaque rupture, as well as periodontal disease, diabetic retinopathy, macular degeneration, acute macular degeneration, wet macular degeneration, tumour growth, anaphylaxis, multiple sclerosis, peptic ulcers, or a syncytial viral infection.

  本发明公开并声明了一系列式(I)的取代螺环哌啶苄胺化合物，其中R如本文所述。更具体地说，本发明的化合物是β-色胺酶的抑制剂，因此可用作治疗关节炎，包括关节炎、类风湿关节炎和其他关节炎症状，如类风湿脊柱炎、痛风性关节炎、创伤性关节炎、风疹性关节炎、银屑病性关节炎、骨关节炎或其他慢性炎症性关节疾病，或关节软骨破坏疾病、眼结膜炎、春季结膜炎、炎性肠病、哮喘、过敏性鼻炎、间质性肺病、纤维化、硬皮病、肺纤维化、肝硬化、心肌纤维化、神经纤维瘤、肥厚性瘢痕、各种皮肤病症，例如特应性皮炎和银屑病、心肌梗死、中风、心绞痛或动脉粥样硬化斑块破裂的其他后果，以及牙周病、糖尿病视网膜病变、黄斑变性、急性黄斑变性、湿性黄斑变性、肿瘤生长、过敏反应、多发性硬化、消化性溃疡或合胞病毒感染的药物。
• [EN] 4-AZAINDOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE 4-AZAINDOLE
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2015049574A1

  公开（公告）日：2015-04-09

  4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.

  4-氮杂吲哚衍生物是肌氨酸乙酰胆碱受体（mAChR）M1的调节剂，可能对预防或疾病修饰或症状性治疗与神经系统疾病（如阿尔茨海默病（AD）或带有Lewy小体的痴呆症（DLB））相关的认知缺陷有效，并且包括4-氮杂吲哚衍生物作为活性成分的药物组合物。
• [4 [4-(AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF
  申请人：CHOI-SLEDESKI Yong Mi

  公开号：US20120245199A1

  公开（公告）日：2012-09-27

  The present invention relates herein to compounds and compositions for the treatment and amelioration of inflammatory disease. Specifically the present invention relates to compounds that having a tryptase inhibition activity and the intermediates thereof, pharmaceutical compositions comprising such compounds, and a method of treating subjects suffering from a condition disease or disorder that can be ameliorated by the administration of an inhibitor of tryptase.

  本发明涉及用于治疗和改善炎症性疾病的化合物和组合物。具体地，本发明涉及具有胰蛋白酶抑制活性及其中间体的化合物，包含这些化合物的药物组合物，以及治疗受试者病情、疾病或障碍的方法，该病情、疾病或障碍可以通过给予胰蛋白酶抑制剂而得到改善。